Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
CONCLUSION: We developed and validated models which separately predict SD and PFD in patients with HFrEF. These models may help clinicians and patients consider therapies targeted at these modes of death.TRIAL REGISTRATION NUMBER: PARADIGM-HF: ClinicalTrials.gov NCT01035255, ATMOSPHERE: ClinicalTrials.gov NCT00853658.PMID:34101002 | DOI:10.1007/s00392-021-01888-x (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - June 8, 2021 Category: Cancer & Oncology Authors: Li Shen Brian L Claggett Pardeep S Jhund William T Abraham Akshay Suvas Desai Kenneth Dickstein Jianjian Gong Lars V K øber Marty P Lefkowitz Jean L Rouleau Victor C Shi Karl Swedberg Michael R Zile Scott D Solomon John J V McMurray Source Type: research
Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
CONCLUSION: We developed and validated models which separately predict SD and PFD in patients with HFrEF. These models may help clinicians and patients consider therapies targeted at these modes of death.TRIAL REGISTRATION NUMBER: PARADIGM-HF: ClinicalTrials.gov NCT01035255, ATMOSPHERE: ClinicalTrials.gov NCT00853658.PMID:34101002 | DOI:10.1007/s00392-021-01888-x (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - June 8, 2021 Category: Cancer & Oncology Authors: Li Shen Brian L Claggett Pardeep S Jhund William T Abraham Akshay Suvas Desai Kenneth Dickstein Jianjian Gong Lars V K øber Marty P Lefkowitz Jean L Rouleau Victor C Shi Karl Swedberg Michael R Zile Scott D Solomon John J V McMurray Source Type: research
Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
ConclusionWe developed and validated models which separately predict SD and PFD in patients with HFrEF. These models may help clinicians and patients consider therapies targeted at these modes of death.Trial registration numberPARADIGM-HF: ClinicalTrials.gov NCT01035255, ATMOSPHERE: ClinicalTrials.gov NCT00853658.Graphics abstract (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - June 8, 2021 Category: Cardiology Source Type: research
The effect of neprilysin and renin inhibition on the renal dysfunction following ischemia ‐reperfusion injury in the rat
RAS blockade by a renin inhibitor (aliskiren) or neprilysin inhibition by sacubitril separately led to significant attenuation in the renal IRI ‐induced renal dysfunction. The combination of aliskiren and sacubitril was more effective than either one alone. AbstractThe natriuretic peptide (NP) system counter ‐regulates the renin‐angiotensin system (RAS), so enhancing the activity of natriuretic peptides (NPs) may be beneficial in conditions when RAS is activated such as ischemia‐reperfusion injury (IRI). Neprilysin is the key enzyme responsible for the degradation of NPs. The effects of neprilysin inhibition or the...
Source: Physiological Reports - March 17, 2021 Category: Physiology Authors: Fayez T. Hammad,
Suhail Al ‐Salam,
Sarah S. AlZaabi,
Maryam M. Alfalasi,
Awwab F. Hammad,
Javed Yasin,
Loay Lubbad Tags: ORIGINAL ARTICLE Source Type: research
Aliskiren
(Source: Reactions Weekly)
Source: Reactions Weekly - February 1, 2021 Category: Drugs & Pharmacology Source Type: research
Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients
Conclusion:
Aliskiren restored endothelial function and induced a more prompt peripheral vasodilation in hypertensive and diabetic patients possibly through the increased production of nitric oxide via the enhanced expression and function of the active phosphorylated form of endothelial nitric oxide synthase. (Source: Journal of Hypertension)
Source: Journal of Hypertension - December 11, 2020 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research
Role of renin blocker (Aliskiren) on Cisplatin induced-nephrotoxicity in rats
. (Source: Toxin Reviews)
Source: Toxin Reviews - December 9, 2020 Category: Toxicology Authors: Saeed Alshahrani Pankaj Tripathi Mohammad Ashafaq Muhammad H. Sultan Sivakumar Sivagurunathan Moni Rina Tripathi Abdul Hakeem Siddiqui Hina Rashid Ali M. Malhan Source Type: research
Functional and molecular evaluation of using aliskiren during acute and chronic partial ureteral obstruction in rat solitary kidney
Publication date: Available online 28 November 2020Source: Life SciencesAuthor(s): Mohamed Essam, Nashwa Barakat, Ahmed Elkashef, Amira Awadalla, A.E. Behery, Mahmoud Abdel-Maboud (Source: Life Sciences)
Source: Life Sciences - November 29, 2020 Category: Biology Source Type: research
Application of supercritical fluid chromatography for separation and quantitation of fifteen co-formulated binary anti-hypertensive medications using a single elution protocol.
Abstract
A facile supercritical fluid chromatography method is proposed to analyze fifteen co-formulated binary anti-hypertensive drug combinations using a customized elution procedure. The effect of mobile phase composition, column back pressure and temperature were suitably optimized for adequate retention, analyte response and resolution. The chromatographic separation of different drug combinations was performed on DCPak P4VP (250 × 4.6 mm, 5 μm) column at 125 bar pressure and 40 °C using photo diode array detector. A linear gradient of CO2 and 0.1% formic acid in methanol provided the best elution ...
Source: Biomedical Chromatography : BMC - November 23, 2020 Category: Biomedical Science Authors: Pandya PA, Shah PA, Shrivastav PS Tags: Biomed Chromatogr Source Type: research
Aliskiren Reduces the Adrenal Zona Glomerulosa Apoptosis and Autophagy in Wistar Rats with 2K1C Hypertension.
Authors: de Matos VS, do Nascimento ALR, Pereira PG, Rabelo K, Andrade CBV, Moraes ACN, Salata C, Araújo VHVO, Ciambarella BT, Bonfim Vieira A, Alves LL, da Silva JFR, de Carvalho JJ
Abstract
Hypertension is a disease classified as primary or secondary, manifested not only by elevation of blood pressure but also involved in structural and functional changes of target organs. Renal artery stenosis is a leading factor of secondary hypertension, and its progress is associated with overactivation of the renin-angiotensin-aldosterone system (RAAS). Aliskiren is a renin inhibiting drug that suppresses RAAS and ...
Source: International Journal of Hypertension - November 6, 2020 Category: Cardiology Tags: Int J Hypertens Source Type: research
Therapeutic effects of various renin angiotensin modulators on hyperglycemia-induced cataract formation in Sprague Dawley rats.
CONCLUSION: Overall, our findings suggest that topical treatment with renin angiotensin modulators delayed the onset of diabetes-induced cataract formation.
PMID: 33016125 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - October 3, 2020 Category: Opthalmology Authors: Shree J, Choudhary R, Bodakhe SH Tags: Eur J Ophthalmol Source Type: research
COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?
PMID: 33034579 [PubMed - as supplied by publisher] (Source: Turk Kardiyoloji Dernegi arsivi)
Source: Turk Kardiyoloji Dernegi arsivi - October 1, 2020 Category: Cardiology Authors: Şen S, Üresin AY Tags: Turk Kardiyol Dern Ars Source Type: research
Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: downregulation of IL-6/JAK2/STAT3 signaling pathway
Publication date: Available online 3 August 2020Source: Saudi Pharmaceutical JournalAuthor(s): Amany A. Azouz, Esraa Saleh, Ali A. Abo-Saif (Source: Saudi Pharmaceutical Journal)
Source: Saudi Pharmaceutical Journal - August 4, 2020 Category: Drugs & Pharmacology Source Type: research
Inpatient Initiation of Sacubitril/Valsartan.
Conclusions: Sacubitril/valsartan should be considered for hemodynamically stable patients with HFrEF (New York Heart Association class II or III), potassium <5.2 mmol/L, without a history of angioedema, and after a 36-hour washout from angiotensin-converting enzyme (ACE) inhibitor or aliskiren, if applicable. An appropriate dose can be determined based on the patient's previous ACE inhibitor or angiotensin receptor blocker dose and/or blood pressure along with patient-specific factors. To overcome barriers of use, the following are recommended: NT-proBNP or BNP with establishment of a new baseline 1 month after initiat...
Source: The Annals of Pharmacotherapy - July 31, 2020 Category: Drugs & Pharmacology Authors: Chilbert MR, Rogers KC, Ciriello DN, Rovelli R, Woodruff AE Tags: Ann Pharmacother Source Type: research
